Results 141 to 150 of about 117,049 (245)

Pharmacokinetics, Safety, and Tolerability of Single‐Dose Dazukibart in Healthy Adults in China and Japan: Results From 2 Randomized, Double‐Blind, Phase 1 Studies

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Dazukibart is a humanized monoclonal antibody selectively targeting interferon‐β. The pharmacokinetics (PK), safety, tolerability, and immunogenicity of dazukibart were evaluated in 2 double‐blind, randomized, placebo‐controlled, single‐dose, Phase 1 studies in healthy adults in China (Study 1: N = 18; dazukibart 900 mg = 15; placebo = 3) and ...
Naihan Chen   +10 more
wiley   +1 more source

Pharmacokinetics, Bioequivalence, and Safety Studies of Crisaborole Ointment in Healthy Chinese Subjects

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract The aim of this study was to evaluate the bioequivalence and safety of a single application of crisaborole ointment to test formulation and reference formulation in healthy subjects under fasting conditions. A total of 32 subjects were included and divided into 2 groups (test‐reference; reference‐test).
Yanchao Wang   +9 more
wiley   +1 more source

Pharmacokinetics, Safety, and Skin Irritation and Sensitization Potential of Clascoterone Cream in Early‐Phase Clinical Study Participants

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Clascoterone is an androgen receptor inhibitor approved for the treatment of acne vulgaris in patients 12 years of age and older. Here, we report results of 5 phase 1 studies that assessed the pharmacokinetics (PK), safety, and skin irritation and sensitization potential of clascoterone cream 1% in healthy participants and patients with acne ...
Andrea Francesco Daniele Di Stefano   +8 more
wiley   +1 more source

Navigating Pharmacogenomic Testing in Practice: Who to Test and When to Test

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
There is increasing attention on the clinical utility and value of pharmacogenetic (PGx) testing to individualize medication management. Most clinical practice guidelines from medical professional societies do not recommend routine PGx testing, with a few key exceptions.
James M. Stevenson   +4 more
wiley   +1 more source

Acute myocarditis according to age: Presentation, management and early outcomes

open access: yesESC Heart Failure, EarlyView.
MIS, multisystem inflammatory syndrome; MRE, myocarditis‐related events (within 30 days included all‐cause death, cardiogenic shock, cardiac arrest, ventricular arrhythmias or complete AV block). Abstract Aims Acute myocarditis (AM) is a rare but severe disease affecting patients of all ages. Large multicentric studies comparing children and adults are
Clément Karsenty   +25 more
wiley   +1 more source

Home - About - Disclaimer - Privacy